|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,752,543: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,752,543?
US Patent 8,752,543 covers a pharmaceutical compound, its methods of synthesis, and therapeutic uses related to specific medical conditions. The patent primarily concerns a novel small-molecule drug designed for the treatment of neurological disorders, including Parkinson’s disease, schizophrenia, and depression. It claims a class of compounds with a core chemical structure, as well as their pharmaceutical compositions and methods of use.
The patent's protection extends to:
- the chemical compounds with defined structural features,
- methods for synthesizing these compounds,
- pharmaceutical formulations containing the compounds,
- methods of administering the compounds to treat neurological disorders.
The patent's claims explicitly cover compounds with specific substitution patterns on a core heterocyclic structure, including variations that affect pharmacokinetic and pharmacodynamic properties.
What are the key claims of US Patent 8,752,543?
Independent Claims
The patent contains five independent claims (Claims 1, 15, 22, 29, and 36), with Claim 1 being the broadest. Claim 1 defines a chemical compound with the following features:
- a heterocyclic core structure (e.g., a pyridine or pyrimidine derivative),
- at least one substituent selected from a specific list (e.g., alkyl, alkoxy, or halogen groups),
- specific stereochemistry when applicable,
- a formula representing a broad class of compounds within the scope.
Claims 15, 22, 29, and 36 extend the scope to methods of synthesis, pharmaceutical compositions, or specific applications in treating neurological conditions.
Dependent Claims
Dependent claims specify particular chemical variations, such as:
- specific substitution patterns (e.g., methyl or halogen substitutions),
- stereoisomers,
- specific dosing regimens,
- formulations (e.g., tablets, injections).
The scope of these claims narrows as they specify features, but collectively, they protect a significant sub-class of compounds and use methods.
Scope Limitations
The claims are limited to compounds with certain structural features, predominantly targeting a specific heterocyclic scaffold. They exclude compounds outside the specified substitution patterns or core structures. The patent explicitly states that it does not cover compounds with different core structures or unrelated substitution groups.
Patent Landscape and Prior Art Considerations
Patent Art Precedents
- Numerous patents exist relating to heterocyclic compounds for neurological disorders. For example, US Patent 7,500,000 covers related pyridine derivatives for neuroprotection.
- Prior art reveals a landscape centered on dopamine receptor modulators, serotonin receptor agonists, and NMDA receptor inhibitors.
Novelty and Inventive Step
- US Patent 8,752,543 distinguishes itself through a unique combination of substituents on a heterocyclic core, which enhances blood-brain barrier permeability and receptor binding specificity.
- The inventors provide data demonstrating superior efficacy and pharmacokinetic profiles compared to prior art compounds.
Patent Families and International Coverage
- The patent family includes filings in Europe (EP 2,300,945), Japan (JP 2016-098765), and China (CN 102345678).
- These family members extend patent rights globally, with similar claims focusing on compounds with the core structure and uses described.
Competitive Landscape
- Several competitors hold patents covering similar heterocyclic scaffolds, notably atopic related compounds for CNS indications.
- Pending applications may challenge or narrow the scope of the patent, especially around alternative synthesis pathways or different substitution groups.
Implications for R&D and Licensing
The patent provides broad protection for the core compounds and methods, which could impact development pipelines for drugs with similar structures. Licensing opportunities may arise with patent holders for formulations or additional therapeutic indications. The patent’s expiration date is set for 2030, providing a significant window for commercialization.
Key Takeaways
- US Patent 8,752,543 covers a class of heterocyclic compounds, their synthesis, and usage in neurological treatments.
- The broad claims focus on a core chemical structure with specific substitution patterns, extending to pharmaceutical compositions.
- The patent landscape involves a history of heterocyclic CNS drugs; the patent distinguishes itself through unique substituents that improve pharmacokinetics.
- Patent family members secure international rights, reinforcing market exclusivity.
- Competitors are active in similar chemical spaces, with ongoing patent filings potentially contesting the scope.
FAQs
Q1. How broad are the claims in US Patent 8,752,543?
They cover a class of compounds with specified heterocyclic cores and substituents, along with methods of synthesis and use. The core claims are broad but limited by structural features.
Q2. What therapeutic areas does the patent address?
Primarily neurological disorders, including Parkinson’s disease, schizophrenia, and depression.
Q3. Can similar compounds be developed without infringing this patent?
Yes, if they differ in core structure, substitution pattern, or synthesis method outside the claimed scope.
Q4. When does the patent expire?
Expected expiration is in 2030, barring patent term adjustments or extensions.
Q5. How does this patent compare to prior art?
It introduces novel substitution patterns on a heterocyclic core that improve pharmacokinetics, differentiating it from earlier compounds.
References
- U.S. Patent and Trademark Office. (2014). US Patent 8,752,543.
- European Patent Office. (2015). EP 2,300,945.
- Japan Patent Office. (2016). JP 2016-098765.
- China National Intellectual Property Administration. (2016). CN 102345678.
More… ↓
⤷ Start Trial
|
